Heart Failure in Cardiomyopathies: A Position Paper from the Heart Failure Association of the European Society of Cardiology
Сердечная недостаточность при кардиомиопатиях: позиционный документ Ассоциации по сердечной недостаточности Европейского общества кардиологов
2019-04-16
SCID: 54.1/wqmwu5dt
Discuss with AI
cardiomyopathiesdilated cardiomyopathyheart failurehypertrophic cardiomyopathyrestrictive cardiomyopathy
Figures from the paper
Abstract (AI)
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.
Key Findings
1
Heart failure in cardiomyopathies has distinct epidemiology, pathophysiology, natural history, and treatment responses across DCM, HCM, and RCM.
2
In dilated cardiomyopathy, HFrEF is highly prevalent, the most frequent cause of death, and a major indication for heart transplantation despite improved treatment.
3
In hypertrophic cardiomyopathy, HFpEF affects most patients with obstructive disease and approximately 10% with non-obstructive disease; advanced HF is uncommon but carries poor prognosis.
4
In restrictive cardiomyopathy, HFpEF is common, whereas HFrEF develops later and is more frequent in amyloidosis or iron overload/haemochromatosis; HF predicts poor outcomes regardless of cause.
5
Mechanism-based and aetiology-specific treatments, including enzyme replacement, transthyretin stabilizers, immunoadsorption, and immunotherapy, may improve outcomes, but effective causal therapies remain unavailable for many cardiomyopathies.
Research Object
Heart failure in patients with dilated, hypertrophic, and restrictive cardiomyopathies
Research Subject
The epidemiology, pathophysiology, natural history, therapeutic responses, and treatment strategies for heart failure in cardiomyopathies
Publication Details
Publication Date
2019-04-16
Journal
Publisher
ISSN
Cited by
417
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2016
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy2014
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death2015
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy2018
Cited by5
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2021
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death2022
2023 ESC Guidelines for the management of cardiomyopathies2023
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2022
Heart failure in dilated non-ischaemic cardiomyopathy2019